Compare Invesco Preferred ETF (PGX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Preferred ETF vs TG Therapeutics Inc — how do they compare? Invesco Preferred ETF trades at $10.02 (market cap $3.60B), while TG Therapeutics Inc trades at $55.27 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 2.3× Invesco Preferred ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Preferred ETF for 94 Days and TG Therapeutics Inc for 15 Days on average.
| PGX | TGTX | |
|---|---|---|
Market Cap | $3.60B | $8.16B |
Volume | 5,986,026 | 1,735,121 |
52-Week High | $11.61 | $59.06 |
52-Week Low | $9.97 | $26.94 |
Typical Hold Time | 94 Days | 15 Days |
Sector | — | Health |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGX trades at $10.005, up 0.35% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks disclosed financial ratios such as P/E and P/S, and no recent income statement or cash flow data is available. Recent corporate actions include dividend payments scheduled for 2026, but current fundamental metrics are not provided.
The outlook for PGX is cautious due to the absence of current financial data and bearish technical signals. Investment opportunities hinge on future earnings visibility and valuation clarity, while risks include potential earnings volatility and market sentiment shifts. Investors should await updated financial disclosures for a clearer assessment.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
